Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

KRX:007570 Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,295	3,414	7,174	9,288	41,341
Short-Term Investments	8,495	10,276	5,419	34,111	1.77
Trading Asset Securities	-	-	-	231.78	269.1
Cash & Short-Term Investments	12,790	13,690	12,593	43,631	41,612
Cash Growth	-6.57%	8.72%	-71.14%	4.85%	15.92%
Accounts Receivable	44,961	47,656	48,762	52,803	58,678
Other Receivables	3,936	4,680	4,716	3,297	6,241
Receivables	48,897	52,336	53,479	56,101	64,945
Inventory	59,873	53,108	48,387	32,423	48,590
Prepaid Expenses	158.02	186.42	303.23	515.3	640.96
Other Current Assets	3,652	4,339	3,656	3,671	6,707
Total Current Assets	125,370	123,659	118,418	136,340	162,496
Property, Plant & Equipment	216,421	181,973	178,244	175,779	185,966
Long-Term Investments	43,510	38,572	52,847	45,029	2,513
Other Intangible Assets	1,888	1,826	1,935	2,078	3,654
Long-Term Deferred Charges	23,453	25,530	29,481	34,392	55,747
Other Long-Term Assets	20,568	21,046	21,991	25,643	28,742
Total Assets	431,211	392,607	402,916	419,261	439,117
Accounts Payable	22,322	26,307	29,813	23,717	23,663
Accrued Expenses	513.8	398.44	310.58	314.19	173.36
Short-Term Debt	92,505	65,789	71,000	92,500	84,256
Current Portion of Long-Term Debt	-	-	2,000	-	18,485
Current Portion of Leases	266.59	522.11	370.52	159.24	-
Current Income Taxes Payable	1,293	1,126	958.54	3,542	3,976
Other Current Liabilities	40,002	45,121	40,875	47,687	46,594
Total Current Liabilities	156,902	139,263	145,328	167,920	177,147
Long-Term Debt	14,700	6,000	-	5,000	-
Long-Term Leases	209.38	339.24	732.69	843.73	300.62
Long-Term Deferred Tax Liabilities	8,934	9,233	10,662	10,464	7,962
Other Long-Term Liabilities	310	50	500	21.5	0
Total Liabilities	189,635	162,207	165,132	192,385	194,195
Common Stock	47,714	47,714	47,714	47,714	47,714
Additional Paid-In Capital	78,370	78,441	78,416	78,590	78,795
Retained Earnings	61,101	53,559	58,759	43,170	31,413
Treasury Stock	-11,269	-11,921	-10,075	-7,437	-7,743
Comprehensive Income & Other	60,966	57,957	58,496	60,587	55,902
Total Common Equity	236,881	225,751	233,311	222,624	206,081
Minority Interest	3,582	3,536	3,361	3,139	37,728
Shareholders' Equity	241,576	230,400	237,785	226,876	244,922
Total Liabilities & Equity	431,211	392,607	402,916	419,261	439,117
Total Debt	107,681	72,650	74,103	98,503	103,041
Net Cash (Debt)	-94,891	-58,960	-61,511	-54,872	-61,429
Net Cash Per Share	-5152.85	-3206.66	-3393.60	-3014.10	-3374.26
Filing Date Shares Outstanding	18.01	17.97	18.09	18.21	18.21
Total Common Shares Outstanding	18.01	17.97	18.09	18.21	18.21
Working Capital	-31,532	-15,604	-26,910	-31,580	-14,651
Book Value Per Share	13150.27	12561.42	12899.45	12228.63	11319.92
Tangible Book Value	234,994	223,925	231,375	220,547	202,427
Tangible Book Value Per Share	13045.48	12459.79	12792.46	12114.49	11119.20
Land	120,507	120,298	120,308	116,955	102,083
Buildings	41,126	42,787	44,474	45,995	57,001
Machinery	4,055	6,060	9,367	9,480	14,843
Construction In Progress	49,583	11,435	2,384	1,953	11,144

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.